ClinicalTrials.gg
RecruitingNCT07527715MPS-CMR-DCMUpdated Apr 14, 2026

Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy

An observational study in Cardiomyopathy, Dilated, Prognosis and Magnetic Resonance Imaging, Cardiac, sponsored by Shandong Provincial Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Shandong Provincial Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Cardiomyopathy, Dilated with a site in China — 13 open to participants now, 14 under way, none of them phase 3. Cardiomyopathy, Dilated · China.

Planned enrollment
2nd of 11
2,000 · median 2,000
Started
2021
with 1 other
Observational
11 of 23
8 open now
Primary completion
2028-12
later than 10 of 13 live
Registered
21st of 23
by date
Lead sponsor
2 of 23
Shandong Provincial Hospital

Among the 23 studies in Cardiomyopathy, Dilated with a site in China, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2021, is one of 11 observational ones, reaches primary completion later than 10 of the 13 other live ones, and was the 21st registered.

Cardiomyopathy, Dilated

256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.

Browse Cardiomyopathy, Dilated studies →

Open to participants now

13 of the 23 studies in Cardiomyopathy, Dilated with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 54 Cardiomyopathy, Dilated studies recruiting now, 31 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 14 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Cardiomyopathy, Dilated with a site in China, or all of them as a file.
02

Study summary

Dilated cardiomyopathy (DCM) is a common and serious heart disease characterized by left ventricular enlargement and impaired pumping function, with adverse prognosis (including heart failure, arrhythmia, heart-related hospitalization, and death) being a major concern for patients. Currently, a critical gap exists in accurately predicting which DCM patients are at high risk of these severe outcomes, limiting targeted clinical care.

This observational, non-invasive study aims to develop and validate a clinical prediction model for early risk warning of adverse prognosis in DCM patients. The model integrates multi-parameter stress perfusion cardiac magnetic resonance (MP stress perfusion CMR)-a safe, high-resolution imaging technique that assesses cardiac structure, function, blood perfusion, and tissue damage under mild stress-and standard clinical data (e.g., age, gender, blood pressure, and routine heart test results).

The model will be trained and tested using follow-up data from hundreds of DCM patients, with the analysis identifying patterns in CMR and clinical data associated with adverse outcomes. Once validated for accuracy, the model will provide doctors with personalized risk scores to prioritize care for high-risk patients (e.g., early intervention, close monitoring) and avoid over-treatment for lower-risk individuals.

Beyond clinical application, the study will enhance understanding of DCM progression, laying the groundwork for improved diagnostic tools, more effective treatments, and better strategies to prevent DCM-related complications, ultimately improving patient quality of life and reducing mortality.

Read the detailed description

The study focuses on a common but serious heart condition called dilated cardiomyopathy (DCM), which affects millions of people worldwide. Dilated cardiomyopathy is a disease where the heart's main pumping chamber (the left ventricle) becomes enlarged and weakened, making pumping function harder for the heart to pump blood efficiently to the rest of the body. For patients with DCM, the biggest concern is the risk of "adverse prognosis"-a category includes serious outcomes like heart failure, abnormal heart rhythms, hospitalizations related to heart problems, or even death. Currently, doctors face challenges in accurately predicting which DCM patients are more likely to experience these severe outcomes, a limitation restricting the ability to provide timely, targeted care to those at highest risk.

To address the gap, the investigators aim to develop and test a "clinical prediction model"-a tool that combines medical data to predict the likelihood of adverse outcomes in DCM patients. The key innovation of the model is the use of a powerful medical imaging technique called multi-parameter stress perfusion cardiac magnetic resonance (MP stress perfusion CMR), combined with standard clinical information about patients.

First, the terms are explained in simple language. Cardiac magnetic resonance (CMR) is a safe, non-invasive imaging test that creates detailed pictures of the heart's structure and function. "Stress perfusion" means that during the CMR scan, the participant's heart is placed under a mild form of stress (usually by administration of a medication that increases heart rate, similar to light exercise) to observe blood flow through the heart muscle during increased workload. "Multi-parameter" refers to the collection of multiple types of information from the CMR scan, such as myocardial contractility, myocardial perfusion, and any damage or scarring in cardiac tissue.

The goal of the study is to use detailed CMR data, along with other basic clinical information (e.g., patient age, gender, blood pressure, and results from standard heart tests), to construct a prediction model. The model will be trained using data from hundreds of DCM patients with existing follow-up records. The investigators will analyze the records to determine which patients experienced adverse outcomes and to identify patterns in CMR and clinical data associated with those outcomes.

Once the model is constructed and tested for accuracy, the tool can be utilized by doctors in clinical practice to assist in the assessment of DCM patients. For example, when a patient is diagnosed with DCM, doctors can perform the CMR scan, input the data into the model, and obtain a personalized risk score indicating the probability of future severe cardiac events in that patient. The resulting information will support clinical decision-making: the scores will allow doctors to prioritize care for high-risk patients-such as early treatment initiation, more frequent monitoring, or medication adjustment-to prevent adverse outcomes. For lower-risk patients, the model can help avoid unnecessary, costly tests or over-treatment.

Beyond individual patient benefits, the study also has broader value for public health and medical research. By better defining the factors (from CMR and clinical data) most closely linked to poor outcomes in DCM, new insights can be gained regarding disease progression. Such insights may lead to improved diagnostic tools, more effective treatments, and enhanced strategies for preventing DCM-related complications in the long term.

Of particular note, the study is observational and non-invasive. All patients receive standard medical care for DCM, and the CMR scan is a routine test already applied in clinical practice. The study will follow patients over time to validate the prediction model, ensuring reliable performance across different subgroups of DCM patients (e.g., varying age, gender, or disease severity).

In summary, the study seeks to bridge a critical gap in the care of DCM patients by creating a reliable, easy-to-use prediction tool based on advanced CMR imaging. By early identification of patients at high risk of adverse outcomes, quality of life can be improved, hospitalizations reduced, and lives potentially saved-while also advancing understanding of the complex heart disease for the benefit of future patients.

03

Conditions studied

  • Cardiomyopathy, Dilated
  • Prognosis
  • Magnetic Resonance Imaging, Cardiac
  • Death, Sudden, Cardiac
  • Heart Failure
  • Risk Assessment
  • Stress Perfusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

During the study period, patients with dilated cardiomyopathy (DCM) who were seen in the cardiology departments of Shandong Provincial Hospital, Jinan Central Hospital, and Beijing Anzhen Hospital, or referred for cardiac magnetic resonance (CMR) assessment, were prospectively enrolled in the registry at the time of scanning.

Eligibility criteria

Inclusion Criteria

1.An elevated left ventricular end-diastolic volume indexed to body surface area and reduced , compared with published age- and gender-specific reference values Exclusion Criteria

  1. significant coronary artery disease (CAD), defined as a stenosis of ˃50% in a major coronary artery
  2. infiltrative disease
  3. valvular cardiomyopathy
  4. arrhythmogenic cardiomyopathy
  5. congenital heart disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Interventions

  • Otherleft ventricular ejection fraction

    HFrEF:LVEF\<40% ; HFmrEF:LVEF40-50%; HFpEF: LVEF\>50%

06

What researchers measure

Primary outcomes

  1. SCD-related events

    SCD, appropriate implantable cardioverter-defibrillator shock, and resuscitated cardiac arrest

    Time frame: 1 year, 3 years, and 5 years after CMR examination

Secondary outcomes

  1. heart failure events

    heart failure-related death, unplanned heart failure hospitalization, or heart transplantation

    Time frame: at 1, 3, and 5 years following CMR

Other outcomes

  1. all-cause mortality

    Time frame: follow-up will be conducted at 1, 3, and 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, Bezzina CR, Biagini E, Blom NA, de Boer RA, De Winter T, Elliott PM, Flather M, Garcia-Pavia P, Haugaa KH, Ingles J, Jurcut RO, Klaassen S, Limongelli G, Loeys B, Mogensen J, Olivotto I, Pantazis A, Sharma S, Van Tintelen JP, Ware JS, Kaski JP; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-3626. doi: 10.1093/eurheartj/ehad194. No abstract available. PubMed 37622657 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be made available to external researchers. The dataset contains sensitive clinical, imaging, and longitudinal prognostic information from patients with dilated cardiomyopathy. Broad sharing of IPD may compromise patient privacy and confidentiality, violate informed consent restrictions, and increase the risk of re-identification. In addition, the multiparametric CMR and artificial intelligence models rely on integrated institutional data that have not been de-identified to a level suitable for unrestricted public or third-party sharing. Therefore, IPD will be retained securely within the study group and will not be shared externally.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Dec 2028, 84 months after the start.

Of 51 observational studies under Cardiomyopathy, Dilated, half reached primary completion within 95 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 101. This study's planned 84 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 14, 2026
StartActual
Dec 1, 2021
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2038
Last update
Apr 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07527715
Lead sponsor
Shandong Provincial Hospital
Responsible party
Wenxian Wang (Principal Investigator, Shandong Provincial Hospital) — Principal investigator
First posted
Apr 14, 2026
Start date
Dec 1, 2021
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2038 (estimated)
Last update
Apr 14, 2026

Study contacts

Wenxian Wang, Dr
Contact
wwx990511@163.com
8617705414294
Xi-ming Wang
study chair · Shandong Provincial Hospital
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion